Client: Eli Lilly
Preparing health systems around the world to respond to the growing Alzheimer’s patient population and advancements in early detection, diagnosis, and treatment is one of the most critical public health challenges of our time. The arrival of new treatment options and diagnostics on the horizon coupled with a projected influx of Alzheimer’s patients creates a heightened sense of urgency. However, many health systems are not ready.
We partnered alongside a pharmaceutical company working in the Alzheimer’s Disease space that was seeking to work with their health system partners as they prepare to increase their readiness to deliver Alzheimer’s Disease care. Together we were tasked with finding ways to support healthcare organizations that need to build better care pathways for Alzheimer's Disease in anticipation of emerging treatment options.